nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

21.05.2017 | Editorial

Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies

verfasst von: D. R. Giacobbe, A. E. Maraolo, C. Viscoli

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Excerpt

Carbapenem-resistant Enterobacteriaceae (CRE) are now endemic in several countries [1]. Infections caused by these organisms are associated with high mortality, with the frequently multidrug-resistant phenotype of CRE being deemed as one of the major culprits [2, 3]. Indeed, clinicians have usually little choice but to use antibiotics with reduced activity; sometimes they do not have any active choice at all. Many clinicians, including ourselves, have therefore started to administer combinations of antimicrobials, mainly with the aim of taking advantage of possible additive or synergistic effects [2]. …

Munoz-Price LS, Poirel L, Bonomo RA et al (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13:785–796CrossRefPubMedPubMedCentral

Tumbarello M, Trecarichi EM, De Rosa FG et al (2015) Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentric study. J Antimicrob Chemother 70:2133–2143CrossRefPubMed

Trecarichi EM, Tumbarello M (2017) Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence [Epub ahead of print]. doi:10.1080/21505594.2017.1292196

Papadimitriou-Olivgeris M, Fligou F, Bartzavali C et al (2017) Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality. Eur J Clin Microbiol Infect Dis. doi:10.1007/s10096-017-2899-6

Paul M, Carmeli Y, Durante-Mangoni E et al (2014) Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:2305–2309CrossRefPubMed

Zusman O, Altunin S, Koppel F et al (2017) Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother 72:29–39CrossRefPubMed

Daikos GL, Tsaousi S, Tzouvelekis LS et al (2014) Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322–2328CrossRefPubMedPubMedCentral

Zusman O, Avni T, Leibovici L, Adler A et al (2013) Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57:5104–5111CrossRefPubMedPubMedCentral

Souli M, Karaiskos I, Masgala A et al (2017) Double-carbapenem combination as salvage therapy for untreatable infections by KPC- 2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis [Epub ahead of print]. doi:10.1007/s10096-017-2936-5

10.

Oliva A, Scorzolini L, Castaldi D et al (2017) Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). J Inf Secur 74:103–106

11.

Garonzik SM, Li J, Thamlikitkul V, Paterson DL et al (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. 168 Antimicrob Agents Chemother 55:3284–3294

12.

Del Bono V, Giacobbe DR, Marchese A et al (2017) Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK/PD root of the paradox? Virulence 8:66–73CrossRefPubMed

13.

Pea F, Della Siega P, Cojutti P et al (2016) Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents 49(2):255–258CrossRefPubMed

14.

Sorlí L, Luque S, Segura C et al (2017) Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa. BMC Infect Dis 17:11CrossRefPubMedPubMedCentral

Titel: Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies
verfasst von: D. R. Giacobbe
A. E. Maraolo
C. Viscoli
Publikationsdatum: 21.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 10/2017
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-017-3010-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2017

Respiratory viral infections are underdiagnosed in patients with suspected sepsis

Does Helicobacter pylori infection increase the risk of adult-onset asthma?

Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong

The use of rapid test QuikRead go® Strep A in bacterial pharyngotonsillitis diagnosing and therapeutic decisions

Evaluation of Mycotube, a modified version of Lowenstein–Jensen (LJ) medium, for efficient recovery of Mycobacterium tuberculosis (MTB)

Prevalence of hereditary hemorrhagic telangiectasia in patients operated for cerebral abscess: a retrospective cohort analysis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin